MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/110/0.1/17.01.25 | Delayed Börse Stuttgart 02:52:24 2024-07-17 am EDT | ||
| 3.24 EUR | -2.11% |
|
| Current month | -9.56% | ||
| 1 month | -8.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 3.24 | -2.11% |
| 24-07-16 | 3.31 | -1.78% |
| 24-07-15 | 3.37 | -2.88% |
| 24-07-12 | 3.47 | +7.10% |
| 24-07-11 | 3.24 | -7.69% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 02:52 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME1GAN |
| ISIN | DE000ME1GAN7 |
| Date issued | 2023-10-03 |
| Strike | 110 $ |
| Maturity | 2025-01-17 (185 Days) |
| Parity | 10 : 1 |
| Emission price | 0.84 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.9 € |
|---|---|
| Lowest since issue | 0.63 € |
| Spread | 0.33 € |
| Spread % | 9.85% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Warrants
- Warrant
